Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide ...

– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a ...

Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...

Mineralys Therapeutics announced the results of the Phase 3 Launch-HTN trial, the largest hypertension study involving an aldosterone synthase inhibitor, which included over 1,000 participants with ...